Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in Refractory Cutaneous Dermatomyositis
NCT05488327Unknown
- Sponsor
- Jiangxi Provincial People's Hospital
- Start
- Aug 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lenalidomide in dermatomyositis (DM), sponsored by Jiangxi Provincial People's Hospital. Primary endpoint: Cutaneous Disease Activity Severity Index activity score at 24 weeks. Status: unknown.
02
Drugs
lenalidomide
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT05488327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05488327.